Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: A Gynecologic Oncology Group Study

Gynecologic Oncology

Volumn 96, Issue 1, 2005, Pages 67-71

  Miller, David Scott ^a   Blessing, John A ^b   Waggoner, Steven ^c   Schilder, Jeanne ^d   Sorosky, Joel ^e   Bloss, Jeffrey ^f   Schilder, Russell ^g  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f University of Missouri   (United States)

^g FOX CHASE CANCER CENTER   (United States)

Author keywords

9 Aminocamptothecin; Ovarian cancer; Primary peritoneal carcinoma

Indexed keywords

9 AMINOCAMPTOTHECIN; HEMOPOIETIC GROWTH FACTOR; PLATINUM DERIVATIVE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD DISEASE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LUNG DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; NEUROLOGIC DISEASE; NEUTROPENIA; OVARY CARCINOMA; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIMARY PERITONEAL CARCINOMA; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TIME; TOXICITY; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 10044237834     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.09.015     Document Type: Article

References (22)

1. D.S. Miller, S.C. Ballon, N.N. Teng, D.B. Seifer, and O.M. Soriero A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma Cancer 57 1986 530 535
2. V.M. Barnabei, D.S. Miller, K.D. Bauer, T.M. Murad, A.W. Rademaker, and J.R. Lurain Flow cytometric evaluation of epithelial ovarian cancer Am. J. Obstet. Gynecol. 162 1990 1584 1590
3. D.S. Miller, N.M. Spirtos, S.C. Ballon, R.S. Cox, O.M. Soriero, and N.N. Teng Critical reassessment of second-look exploratory laparotomy for epithelial ovarian carcinoma. Minimal diagnostic and therapeutic value in patients with persistent cancer Cancer 69 1992 502 510
4. M. Markman, and W. Hoskins Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population J. Clin. Oncol. 10 1992 513 514
5. A. Manetta, J.A. Blessing, and J.A. Hurteau Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group Gynecol. Oncol. 68 1998 45 46
6. M. Markman, J.A. Blessing, D. Moore, H. Ball, and S.S. Lentz Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a gynecologic oncology group phase II trial Gynecol. Oncol. 69 1998 226 229
7. S.C. Plaxe, J.A. Blessing, M.A. Morgan, and J. Carlson Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a gynecologic oncology group study Am. J. Clin. Oncol. 25 2002 45 47
8. P.M. Fracasso, M.F. Brady, D.H. Moore, J.L. Walker, P.G. Rose, and L. Letvak Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study J. Clin. Oncol. 19 2001 2975 2982
9. M.A. Hoffman, J.A. Blessing, and M. Morgan Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A gynecologic oncology group study Gynecol. Oncol. 79 2000 463 465
10. M. Markman, J.A. Blessing, K. DeGeest, M. Morgan, K.Y. Look, and T.J. Herzog Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a gynecologic oncology group trial Gynecol. Oncol. 75 1999 444 446
11. P.G. Rose, J.A. Blessing, H.G. Ball, J. Hoffman, D. Warshal, and K. DeGeest A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group study Gynecol. Oncol. 88 2003 130 135
12. P. Pantazis, A.J. Kozielski, J.T. Mendoza, and J.A. Early Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro Int. J. Cancer 53 1993 863 871
13. E. Rubin, V. Wood, A. Bharti, D. Trites, C. Lynch, and S. Hurwitz A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin Clin. Cancer Res. 1 1995 269 276
14. W. Dahut, C. Takimoto, C. Allegra, J.M. Hamilton, J.M. Sorensen, and S. Arbuck Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult patients J. Clin. Oncol. 14 1996 1236 1244
15. M.A. Bookman Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the gynecologic oncology group (GOG-0182) Semin. Oncol. 29 2002 20 31
16. B.C. Giovanella, J.S. Stehlin, M.E. Wall, M.C. Wani, A.W. Nicholas, and L.F. Liu DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts Science 246 4933 1989 1046 1048
17. F.M. Muggia, I. Liebes, M. Hazarika, S. Wadler, A. Hamilton, and G. Hornreich Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as fractions over 14 days Anti-Cancer Drugs 13 2002 819 825
18. H. Hochster, E.R. Plimack, C.D. Runowicz, J. Speyer, R.C. Wallach, and J. Sorich Biweekly 72-hour 9-aminocamptothecin infusion as a second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group JCO 22 2004 120 126
19. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J. Clin. Oncol. 19 2001 3312 3322
20. B. Lund, O.P. Hansen, K. Theilade, H. Mogens, and J.P. Neijt Phase II study of gemcitabine (2′2′difluorodeoxycytidine) in previously treated ovarian cancer patients J. Natl. Cancer Inst. 86 1994 1530 1533
21. J.D. Shapiro, M.J. Millward, D. Rischin, M. Michael, V. Walcher, and P.A. Francis Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel Gynecol. Oncol. 63 1996 89 93
22. M.A. Bookman, H. Malmstrom, G. Bolis, A. Gordon, A. Lissoni, and J.B. Krebs Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel JCO 16 1998 3345 3352